-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2023-505911-19-00
4
2024-01-05
Acute Myeloid Leukemia
-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2023-503295-25-00
10
2023-10-31
Resectable biliary tract cancers
-
2022-502154-13-00
5
2023-10-27
Patients with well to moderately differentiated neuroendocrine tumors
-
2022-502597-16-00
9
2023-10-27
Intermediate or High-risk Primary or Secondary
Myelofibrosis
-
2023-510431-11-00
4
2023-07-21
Chronic Lymphocytic Leukemia
-
2024-519347-15-00
4
2023-06-27
Oligometastatic prostate carcinoma
-
2024-518710-11-00
4
2023-06-12
Metastatic pancreatic ductal adenocarcinoma (mPDAC)
-
2024-513312-95-00
7
2023-05-30
Part B+C. Primary central nervous system lymphoma (PCNSL)
-
2022-501308-90-00
4
2023-05-24
Molecularly selected and resectable primary colorectal cancer
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2024-511659-17-00
4
2023-05-01
Solid tumors
-
2023-505189-26-00
9
2023-03-28
Advanced esophageal squamous cell carcinoma
-
2024-513578-23-00
4
2023-03-21
Tumors harboring BRAF alterations
-
2024-514666-39-00
4
2023-03-16
Extensive-Stage Small-Cell Lung Cancer (ES SCLC)
-
2024-511631-10-00
9
2023-02-27
Hodgkin’s lymphoma
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-508852-21-00
4
2022-06-10
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
-
2024-515681-14-00
4
2022-05-02
Stage II (pT4)/III colorectal cancer with positive circulating tumor D
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2023-508881-14-00
9
2022-03-21
Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic sy